FDA Inspection 1234088 — KP Pharmaceutical Technology

KP Pharmaceutical Technology — FEI 3001802820

The FDA completed an inspection of KP Pharmaceutical Technology on March 21, 2024 in Bloomington, IN. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). 9 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Official Action Indicated (OAI) (OAI)
End Date
March 21, 2024
Fiscal Year
2024
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Bloomington, IN (United States)

Citations

IDCFRDescription
110521 CFR 211.22(d)Procedures not in writing, fully followed
142121 CFR 211.42(c)(10)Aseptic Processing Area
143421 CFR 211.42(c)(10)(iv)Environmental Monitoring System
143521 CFR 211.42(c)(10)(v)Cleaning System
145121 CFR 211.113(b)Procedures for sterile drug products
202721 CFR 211.192Investigations of discrepancies, failures
203121 CFR 211.194(a)Complete test data included in records
240421 CFR 211.194(a)(6)Comparison of Test Results to Specifications
360321 CFR 211.160(b)Scientifically sound laboratory controls